Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies

Blood

Volumn 122, Issue 16, 2013, Pages 2837-2847

  Nayar, Utthara ^a   Lu, Pin ^a,c   Goldstein, Rebecca L ^a   Vider, Jelena ^b,d   Ballon, Gianna ^a   Rodina, Anna ^b   Taldone, Tony ^b   Erdjument Bromage, Hediye ^b   Chomet, Max ^a   Blasberg, Ronald ^b   Melnick, Ari ^a   Cerchietti, Leandro ^a   Chiosis, Gabriela ^b   Wang, Y Lynn ^a,c   Cesarman, Ethel ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALVESPIMYCIN; CELL PROTEIN; FLICE INHIBITORY PROTEIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; OBATOCLAX; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P50; PROTEIN P52; PROTEOME; TANESPIMYCIN; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; VASCULOTROPIN; VIRAL PROTEIN; 1,3 BENZODIOXOLE DERIVATIVE; 9H-PURINE-9-PROPANAMINE, 6-AMINO-8-((6-IODO-1,3-BENZODIOXOL-5-YL)THIO)-N-(1-METHYLETHYL)-; PURINE DERIVATIVE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASCITES; AUTOPHAGOSOME; AUTOPHAGY; CELL SURVIVAL; CONTROLLED STUDY; DIFFUSE LARGE B-CELL LYMPHOMA CELL LINE; DNA CONTENT; EPSTEIN BARR VIRUS; EX VIVO STUDY; HERPESVIRIDAE; HODGKIN LYMPHOMA CELL LINE; IMMUNOBLOTTING; IN VITRO STUDY; KAPOSI SARCOMA; LYMPHOBLASTOID CELL LINE; LYMPHOMA CELL; LYMPHOMA CELL LINE; MASS SPECTROMETRY; MOUSE; MTT ASSAY; NONHUMAN; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEOMICS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL PROLIFERATION; CHEMISTRY; GAMMAHERPESVIRINAE; HERPES VIRUS INFECTION; HUMAN; METABOLISM; NEOPLASM; PROCEDURES; TUMOR CELL LINE; VIROLOGY;

ANIMALS; APOPTOSIS; AUTOPHAGY; BENZODIOXOLES; CELL LINE, TUMOR; CELL PROLIFERATION; GAMMAHERPESVIRINAE; HERPESVIRIDAE INFECTIONS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NF-KAPPA B; PROTEOME; PROTEOMICS; PURINES; SIGNAL TRANSDUCTION; VIRAL PROTEINS;

EID: 84887440198     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-479972     Document Type: Article

References (40)

1. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006;31(3):164-172.
2. Field N, Low W, Daniels M, et al. KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci. 2003;116(Pt 18):3721-3728.
3. Cheung RK, Dosch HM. The growth transformation of human B cells involves superinduction of hsp70 and hsp90. Virology. 1993;193(2):700-708.
4. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332(18):1186-1191.
5. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266(5192):1865-1869.
6. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86(4):1276-1280.
7. Qin Z, DeFee M, Isaacs JS, Parsons C. Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV. Virology. 2010; 403(1):92-102.
8. Wen KW, Damania B. Hsp90 and Hsp40/Erdj3 are required for the expression and anti-apoptotic function of KSHV K1. Oncogene. 2010;29(24): 3532-3544.
9. Wang L, Dittmer DP, Tomlinson CC, Fakhari FD, Damania B. Immortalization of primary endothelial cells by the K1 protein of Kaposi’s sarcoma-associated herpesvirus. Cancer Res. 2006;66(7): 3658-3666.
10. Chen W, Sin SH, Wen KW, Damania B, Dittmer DP. Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLoS Pathog. 2012;8(11):e1003048.
11. Sun X, Barlow EA, Ma S, et al. Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism. Proc Natl Acad Sci USA. 2010; 107(7):3146-3151.
12. Jeon YK, Park CH, Kim KY, et al. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation. J Pathol. 2007;213(2):170-179.
13. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol. 1998;42(4):273-279.
14. Chiosis G, Lucas B, Huezo H, Solit D, Basso A, Rosen N. Development of purine-scaffold small molecule inhibitors of Hsp90. Curr Cancer Drug Targets. 2003;3(5):371-376.
15. Holland JP, Caldas-Lopes E, Divilov V, et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS ONE. 2010;5(1):e8859.
16. Chiosis G, Neckers L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol. 2006;1(5):279-284.
17. Cerchietti LC, Lopes EC, Yang SN, et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6dependent B cell lymphomas. Nat Med. 2009; 15(12):1369-1376.
18. Moulick K, Ahn JH, Zong H, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol. 2011; 7(11):818-826.
19. Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood. 2000; 96(7):2537-2542.
20. Keller SA, Hernandez-Hopkins D, Vider J, et al. NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood. 2006;107(8):3295-3302.
21. Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med. 2004;199(7):993-1003.
22. Lee JS, Li Q, Lee JY, et al. FLIP-mediated autophagy regulation in cell death control. Nat Cell Biol. 2009;11(11):1355-1362.
23. Kataoka T, Budd RC, Holler N, et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol. 2000;10(11):640-648.
24. Zuehlke A, Johnson JL. Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers. 2010;93(3):211-217.
25. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci. 2007;1113:202-216.
26. An FQ, Folarin HM, Compitello N, et al. Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi’s sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol. 2006;80(10):4833-4846.
27. Grossmann C, Ganem D. Effects of NFkappaB activation on KSHV latency and lytic reactivation are complex and context-dependent. Virology. 2008;375(1):94-102.
28. Vieira J, O’Hearn PM. Use of the red fluorescent protein as a marker of Kaposi’s sarcoma-associated herpesvirus lytic gene expression. Virology. 2004;325(2):225-240.
29. Jeong JH, Orvis J, Kim JW, McMurtrey CP, Renne R, Dittmer DP. Regulation and autoregulation of the promoter for the latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus. J Biol Chem. 2004; 279(16):16822-16831.
30. Wang SA, Chuang JY, Yeh SH, et al. Heat shock protein 90 is important for Sp1 stability during mitosis. J Mol Biol. 2009;387(5):1106-1119.
31. Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ. 2006; 13(8):1419-1421.
32. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621-681.
33. Park HJ, Lee SJ, Kim SH, et al. IL-10 inhibits the starvation induced autophagy in macrophages via class I phosphatidylinositol 3-kinase (PI3K) pathway. Mol Immunol. 2011;48(4):720-727.
34. Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator [published correction appears in Nature. 1998;392(6672):210]. Nature. 1998;391(6662): 86-89.
35. Ma Q, Cavallin LE, Yan B, et al. Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi’s sarcoma. Proc Natl Acad Sci USA. 2009; 106(21):8683-8688.
36. Higashi C, Saji C, Yamada K, et al. The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells. Biol Pharm Bull. 2012;35(5):725-730.
37. Mesri EA, Cesarman E, Boshoff C. Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010;10(10):707-719.
38. Caldas-Lopes E, Cerchietti L, Ahn JH, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA. 2009;106(20):8368-8373.
39. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 2012;1823(3):742-755.
40. Cannon JS, Nicholas J, Orenstein JM, et al. Heterogeneity of viral IL-6 expression in HHV-8associated diseases. J Infect Dis. 1999;180(3): 824-828.